-56%

est. 2Y upside i

HealthcareSeries A

Junction (fka Vital) provides infrastructure for healthcare organizations, making patient data accessible, actionable, and automated across lab testing and device integrations. Our mission is to reduce the cost of managing chronic disease by two orders of magnitude.

Rank

#251

Sector

Healthcare Infrastructure

Est. Liquidity

~5Y

Data Quality

Data: Medium

Junction presents a strong upside opportunity for a job seeker, driven by its position in a massive and growing healthcare infrastructure market ($250B TAM) and demonstrated exponential growth in customer adoption and data processing.

Last updated: March 10, 2026

Bull (30%)+400%

Junction rapidly expands its API network and deepens integrations with major lab networks and device manufacturers, becoming the de-facto standard for healthcare data infrastructure. This market leadership drives revenue to over $100M ARR by 2028, justifying a 5x valuation of ~$645M, well above the current Series A pricing.

Base (40%)+100%

Junction continues to grow steadily, expanding its customer base and increasing usage among existing clients. It successfully fends off smaller competitors and maintains its niche, reaching approximately $50M ARR by 2028 and achieving a 2x valuation of ~$258M, providing a solid return for early employees.

Bear (30%)-80%

A dominant incumbent like Epic or Cerner launches a directly competing, modern API solution, or a well-funded competitor gains significant traction, commoditizing Junction's offering. Growth stalls, leading to a down round or acquisition at a valuation of ~$25M, which, after accounting for the $21.4M investor liquidation preference, results in a near-total loss for common stock holders.

Est. time to liquidity~5.0 years

Preference Stack Risk

moderate

Investors hold $21.4M in liquidation preferences. In an exit at or below this amount, common stock holders would receive little to nothing.

Dilution Risk

high

As a Series A company, Junction will likely undergo multiple additional funding rounds, leading to significant dilution for common stock holders.

Secondary Liquidity

none

Given its early stage and valuation, there is currently no active secondary market or tender offers for Junction's equity.

Engineering — 5 roles

All functions — 1 role

People — 1 role

Sales — 1 role

View all 8 open roles at Junction →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Junction's data — designed to show you've done your homework.

  • 1

    “How does Junction plan to maintain its competitive moat against potential moves by large EHR vendors like Epic or Cerner, especially if they decide to modernize their own API offerings for lab and device data?”

  • 2

    “Given the company's 'exponential growth' in supporting 500,000+ lab tests and 2 million+ connected devices annually, what are the key metrics the team is focused on to drive revenue growth and achieve profitability in the next 2-3 years?”

  • 3

    “As a Series A company, what is the anticipated timeline for future funding rounds and potential liquidity events for employees, and how does the company plan to manage dilution for common stock holders?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.